Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffb6733d508ccf6e676e188ac65a9063 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2020-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12c0c87e24b15d659ac898f455b30e96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f364cad063b16bc4db94aafc7344298d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d3e2d65fc5e7738dac1ac6706dab7b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9db9db80a76989855248ab796299a596 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3737fbcbdac630532cc54919921f543a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_683a1908e957e41cc96bd3417a0e71e3 |
publicationDate |
2022-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3999535-A1 |
titleOfInvention |
Specific ackr2 modulators for use in therapy |
abstract |
The application discloses a specific ACKR2 modulator for use in the treatment of a proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such a specific ACKR2 modulator and one or more immune checkpoint modulators, preferably one or more immune checkpoint inhibitors. |
priorityDate |
2019-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |